Main content

    Addiction and Pharmacology Research (APRL) Clinical Trials

    APRL Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder
    Description: The multi-site trial will enroll 346 patients in a randomized, double blind, placebo-controlled study of gabapentin enacarbil in patients with Alcohol Use Disorder (AUD) at 10 sites across the U.S. It will assess the safety and efficacy of 1,200 mg of gabapentin (administered in two daily doses of 600 mg), compared with placebo, to reduce drinking in patients who report four or more symptoms of AUD (as defined in the Diagnostic and Statistical Manual of Mental Disorders, DSM-5). Eligible participants will receive either gabapentin enacarbil or placebo for 26 weeks. The study will evaluate whether participants using the medication are more likely to abstain from heavy drinking during the last four weeks of treatment.
    Investigator: John Mendelson, MD
    Eligibility: Males and females, 21 years of age and older, who have a diagnosis of AUD and are seeking treatment
    Status: Active and open to enrollment
    Contact: Kathleen Garrison, 415-600-1652, Email: GarrisK@cpmcri.org about Study HORIZANT

    Title: A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence
    Description: Study of a novel texting intervention for methamphetamine dependence
    Investigator: Gantt Galloway, Pharm. D.
    Eligibility: Males and females, 18 years of age and older, who want to quit methamphetamine dependence
    Status: Active and open to enrollment
    Contact: Kathleen Garrison, 415-600-1652, Email: GarrisK@cpmcri.org about Study Text Message Study

    • updated August 2015

    Back to top